Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Market Cap | $11 | $58 | $29 | $6 |
| - Cash | $2 | $4 | $1 | $0 |
| + Debt | $2 | $0 | $0 | $0 |
| Enterprise Value | $11 | $54 | $28 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4,163.2% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67.6% | 77.4% | – | – |
| EBITDA | -$3 | -$17 | -$5 | -$2 |
| % Margin | -813.3% | -207,095.9% | – | – |
| Net Income | -$3 | -$78 | -$8 | -$2 |
| % Margin | -852.4% | -931,940.1% | – | – |
| EPS Diluted | -0.007 | -0.24 | -0.051 | -0.025 |
| % Growth | 97.3% | -367.8% | -108.5% | – |
| Operating Cash Flow | $9 | -$8 | -$1 | -$1 |
| Capital Expenditures | -$5 | -$0 | -$0 | -$0 |
| Free Cash Flow | $4 | -$9 | -$2 | -$1 |